{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:14:32Z","timestamp":1786990472525,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"am","delay-in-days":309,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["117R034"],"award-info":[{"award-number":["117R034"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["121C063"],"award-info":[{"award-number":["121C063"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["2236 CoCirculation2"],"award-info":[{"award-number":["2236 CoCirculation2"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijbiomac.2022.09.257","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T19:03:15Z","timestamp":1664650995000},"page":"1487-1499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"PA","title":["Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction"],"prefix":"10.1016","volume":"222","author":[{"given":"Nafia G\u00f6k\u00e7e","family":"Ulusoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiye","family":"Emirda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"S\u00f6zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed O.","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halilibrahim","family":"\u00c7ift\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Aksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap \u015eahin","family":"B\u00f6l\u00fckba\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurettin","family":"Yayl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Karay\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zgen","family":"Alanku\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belgin","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11591840-000000000-00000","article-title":"Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients","volume":"25","author":"Breccia","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of chronic myeloid leukemia in advanced phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0015","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.2174\/0929867325666180607092451","article-title":"A chemical approach to overcome tyrosine kinase inhibitors resistance: learning from chronic myeloid leukemia","volume":"26","author":"Zanforlin","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0020","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.3390\/molecules25184210","article-title":"Bcr-Abl allosteric inhibitors: where we are and where we are going to","volume":"25","author":"Carofiglio","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1389557518666181017124854","article-title":"Chronic myeloid leukemia: existing therapeutic options and strategies to overcome drug resistance","volume":"19","author":"Singh","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","article-title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)","volume":"57","author":"Walz","year":"2006","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0035","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1517\/14656566.2011.597741","article-title":"The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose","volume":"12","author":"Breccia","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1248\/cpb.c18-00703","article-title":"Development of a potent protein degrader against oncogenic BCR-ABL protein","volume":"67","author":"Shibata","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0045","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11899-021-00658-w","article-title":"Future directions in chronic phase CML treatment","volume":"16","author":"Javidi-Sharifi","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0055","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fonc.2019.00665","article-title":"New approaches and treatment combinations for the management of chronic myeloid leukemia","volume":"9","author":"Westerweel","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111664","article-title":"Natural products as important tyrosine kinase inhibitors","volume":"182","author":"Yin","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0065","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/cbdd.12983","article-title":"Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia","volume":"90","author":"Parcha","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0070","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cbdv.200890125","article-title":"Two new triterpene saponins from the anti-inflammatory saponin fraction of Ilex pubescens root","volume":"5","author":"Wang","year":"2008","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ptr.1277","article-title":"Protective effect of Astragalus corniculatus saponins against myeloid graffi tumour in hamsters","volume":"18","author":"Karasteva","year":"2004","journal-title":"Phytotherapy Res."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1248\/cpb.53.1451","article-title":"Antitumor activity of Pulsatilla koreana saponins and their structure-activity relationship","volume":"53","author":"Bang","year":"2005","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0085","series-title":"Chemistry And Pharmacology of Natural Products: Saponins","author":"Hostettmann","year":"1995"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0031-9422(91)85281-4","article-title":"Four triterpenoid saponins from dried roots of Gypsophila species","volume":"30","author":"Frechet","year":"1991","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0095","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.carres.2011.07.027","article-title":"New triterpenoid saponins from the roots of Gypsophila perfoliata Linn","volume":"346","author":"Chen","year":"2011","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0100","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/0031-9422(91)85020-Z","volume":"30","author":"Henry","year":"2005","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejmech.2014.05.084","article-title":"Synthesis, antimicrobial and cytotoxic activities, and structure-activity relationships of gypsogenin derivatives against human cancer cells","volume":"82","author":"Emirdag-Ozturk","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bioorg.2013.12.001","article-title":"Synthesis, characterization and in vitro anti-neoplastic activity of gypsogenin derivatives","volume":"53","author":"Ozturk","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.phytochem.2014.11.021","article-title":"Phytochemistry antiproliferative quillaic acid and gypsogenin saponins from Saponaria officinalis L. roots","volume":"113","author":"Lu","year":"2015","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2058739218818958","article-title":"Inhibitory effect of Gypsophila oldhamiana gypsogenin on NCI-N87 gastric cancer cell line","volume":"16","author":"Liu","year":"2018","journal-title":"Eur. J. Inflamm."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0125","doi-asserted-by":"crossref","first-page":"18898","DOI":"10.1039\/C9NJ04287C","article-title":"Synthesis of gypsogenin and gypsogenic acid derivatives with antitumor activity by damaging cell membranes","volume":"43","author":"Wu","year":"2019","journal-title":"New J. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0130","doi-asserted-by":"crossref","first-page":"10945","DOI":"10.3390\/ijms222010945","article-title":"EGFR-targeted pentacyclic triterpene analogues for glioma therapy","volume":"22","author":"Ciftci","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0135","article-title":"Synthesis of gypsogenin derivatives with capabilities to arrest cell cycle and induce apoptosis in human cancer cells","volume":"5","author":"Zhang","year":"2018","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0140","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1248\/bpb.b17-00902","article-title":"The first pentacyclic triterpenoid gypsogenin derivative exhibiting anti-ABL1 kinase and anti-chronic myelogenous leukemia activities","volume":"41","author":"Ciftci","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0145","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.3390\/molecules24193535","article-title":"Design, synthesis and biological evaluation of pentacyclic triterpene derivatives: optimization of anti-ABL kinase activity","volume":"24","author":"Ciftci","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0150","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1021\/jo960057x","article-title":"Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures","volume":"61","author":"Abdel-Magid","year":"1996","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0155","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1021\/op0601013","article-title":"A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes","volume":"10","author":"Abdel-Magid","year":"2006","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0165","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","article-title":"Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges","volume":"12","author":"Soverini","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0170","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1471-4892(01)00063-7","article-title":"Natural products in anticancer therapy","volume":"1","author":"da Rocha","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0175","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13659-020-00293-7","article-title":"Natural products in cancer therapy: past, present and future","volume":"11","author":"Huang","year":"2021","journal-title":"Nat. Prod. Bioprospect."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0180","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/1385272824666200312125734","article-title":"Natural products containing olefinic bond: important substrates for semi-synthetic modification towards value addition","volume":"24","author":"Singh","year":"2020","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"L\u00fc","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0190","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1023\/A:1009623222534","article-title":"Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells","volume":"5","author":"Fernandez-Luna","year":"2000","journal-title":"Apoptosis"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0200","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-Xl","volume":"191","author":"Horita","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0205","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18388\/abp.2013_2014","article-title":"Role of anti-apoptotic pathways activated by BCR\/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"60","author":"Danisz","year":"2013","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0215","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0220","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cbf.3120","article-title":"Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape","volume":"33","author":"Farooqi","year":"2015","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13321-017-0202-6","article-title":"Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study","volume":"9","author":"Van Den Driessche","year":"2017","journal-title":"J. Cheminform."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0235","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1039\/D0NP00084A","article-title":"Semi-synthesis as a tool for broadening the health applications of bioactive olive secoiridoids: a critical review","volume":"38","author":"Oliverio","year":"2021","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0240","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.1038\/s41598-017-09129-w","article-title":"A clue to unprecedented strategy to HIV eradication: \"Lock-in and apoptosis\"","volume":"7","author":"Tateishi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0245","doi-asserted-by":"crossref","first-page":"1900170","DOI":"10.1002\/ardp.201900170","article-title":"Discovery and structure-activity relationship of plastoquinone analogues as anticancer agents against chronic myelogenous leukemia cells","volume":"352","author":"Ciftci","year":"2019","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103255","article-title":"Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents","volume":"92","author":"Bayrak","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105160","article-title":"Design, synthesis and investigation of the mechanism of action underlying anti-leukemic effects of the quinolinequinones as LY83583 analogs","volume":"114","author":"Ciftci","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109555","article-title":"Structure based design, synthesis, and evaluation of anti-CML activity of the quinolinequinones as LY83583 analogs","volume":"345","author":"Bayrak","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ijbiomac.2022.09.257_bb0265","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/molecules27030693","article-title":"In vitro and in silico study of analogs of plant product plastoquinone to be effective in colorectal cancer treatment","volume":"27","author":"Ciftci","year":"2022","journal-title":"Molecules"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022021961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022021961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T06:03:36Z","timestamp":1762236216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022021961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":53,"alternative-id":["S0141813022021961"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.257","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}